Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
29/08/2025
Musk hopes to move the Securities and Exchange Commission's lawsuit against Twitter shares from Washington, D.C. to Texas.
Latest
1 m ago
Cao Qingyao, a counselor to the Chongqing Municipal Government, is under review and investigation.
2 m ago
According to Every Day Economic News, Pacific Securities released a research report on August 29th, giving a buy rating to Haoyuan Medicine (688131.SH). The rating reasons mainly include: 1) rapid growth of front-end business, continuous expansion of product categories; 2) stable growth of back-end business, rapid growth in hand orders.
2 m ago
Every Economic AI Express, Pacific Securities released a research report on August 29, giving Xgimi Technology (688696.SH) a buy rating. The reasons for the rating mainly include: 1) The profit in Q2 2025 turned losses into gains, and the projector main business resumed steady performance; 2) The gross and net profit margins in Q2 2025 both increased, with a significant decrease in the sales expense ratio; 3) The car-mounted business achieved a breakthrough in mass production, and the brand continued to expand overseas. (Daily Economic News)
2 m ago
China antibody-B (03681.HK) completes the issuance of 24.9654 million subscribed shares.
2 m ago
Every AI Express, Pacific released a research report on August 29th, giving Ailis (688578.SH) a buy rating. The rating reasons mainly include: 1) Continuously improve marketing network and production capacity construction; 2) Smooth progress of domestic clinical projects under research; 3) Ailis cooperates with ArriVent to jointly promote overseas clinical trials of 2 rare mutations. (Daily Economic News)
See all latest